From the Department of Hepatobiliopancreatic Surgery, West China Hospital of Sichuan University, Chengdu, Sichuan Province, the People's Republic of China.
Pancreas. 2014 Oct;43(7):1003-8. doi: 10.1097/MPA.0000000000000153.
The objective of this study was to evaluate the clinical consistency of the new World Health Organization 2010 grading and the European Neuroendocrine Tumor Society 2006 TNM staging systems on the surgical outcome for patients with pancreatic neuroendocrine tumors (p-NETs). Moreover, we will discuss their prognostic value.
The medical records of 110 consecutive patients with p-NETs who were surgically treated in our center from January 2002 to December 2012 were reviewed.
Sixty-five patients were diagnosed as having neuroendocrine tumor G1, 27 patients had neuroendocrine tumor G2, 14 patients had neuroendocrine carcinoma G3, and 4 patients had mixed adenoneuro endocrine carcinoma; the survival rates at 5 years were 82.6%, 52.7%, 25.7%, and 0%, respectively (P < 0.001). The TNM stage was I in 48 patients, II in 39 patients, III in 11 patients, and IV in 12 patients; the 5-year survival rates were 83.1%, 72.1%, 0%, and 0%, respectively (P < 0.001). The patients who underwent R0 resection gained a statistically longer survival time than those who did not (P < 0.001).
Both classifications accurately reflect the clinical outcome of p-NETs. Surgical margin, the World Health Organization 2010 grading, and the TNM staging systems may all be meaningful prognostic factors impacting the long-term survival of patients with p-NETs.
本研究旨在评估新的世界卫生组织 2010 年分级系统和欧洲神经内分泌肿瘤学会 2006 年 TNM 分期系统在胰腺神经内分泌肿瘤（p-NET）患者手术结果方面的临床一致性。此外，我们将讨论它们的预后价值。
回顾了 2002 年 1 月至 2012 年 12 月在我院接受手术治疗的 110 例连续 p-NET 患者的病历。
65 例患者诊断为神经内分泌肿瘤 G1，27 例患者诊断为神经内分泌肿瘤 G2，14 例患者诊断为神经内分泌癌 G3，4 例患者诊断为混合性腺神经内分泌癌；5 年生存率分别为 82.6%、52.7%、25.7%和 0%（P<0.001）。TNM 分期为 I 期 48 例，II 期 39 例，III 期 11 例，IV 期 12 例；5 年生存率分别为 83.1%、72.1%、0%和 0%（P<0.001）。RO 切除患者的生存时间明显长于未行 RO 切除患者（P<0.001）。
两种分类均能准确反映 p-NET 的临床结果。手术切缘、世界卫生组织 2010 年分级和 TNM 分期系统可能都是影响 p-NET 患者长期生存的有意义的预后因素。
